Myxoid liposarcoma associated with adalimumab treatment: A case report
- Authors:
- Carmen Rodríguez-Cerdeira
- José Ignacio Neissa-Vasquez
- Miguel Carnero-Gregorio
- Concepción Fiaño-Valverde
- Victor Muñoz-Garzón
View Affiliations
Affiliations: Efficiency, Quality and Costs in Health Services Research Group (EFISALUD), Health Research Institute, SERGAS-UVIGO, 36200 Vigo, Spain, Department of Histopathology, Álvaro Cunqueiro Hospital, CHUVI, 36312 Vigo, Spain, Department of Radiotherapy, Meixoeiro Hospital, CHUVI, 36200 Vigo, Spain
- Published online on: February 27, 2019 https://doi.org/10.3892/mco.2019.1817
-
Pages:
454-456
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Biological agents that suppress inflammation, such as tumour necrosis factor (TNF-α) inhibitors, are being successfully used at an increasing frequency for the treatment of chronic inflammatory diseases, such as psoriasis. However, these drugs are not free of side effects, and although the general rates of malignancy in patients using anti-TNF-α therapies are not high, certain tumours of cutaneous origin, particularly carcinomas, have been reported. We herein present the case of a 47-year-old female patient with moderate-to-severe psoriasis for 20 years under treatment with adalimumab administered at the standard dose of 40 mg, injected subcutaneously each fortnight, with good efficacy. To the best of our knowledge, this is the first reported case of a low-grade (grade 1) myxoid liposarcoma in a patient receiving treatment with adalimumab since 2009. A review of the relevant literature was also conducted. Continuous investigation of such cases is crucial in order to elucidate the iatrogenic risk of rare cancers, such as myxoid liposarcoma, in patients undergoing treatment with currently available as well as future biological therapies.
View References
|
1
|
Augustin M, Langenbruch A, Gutknecht M,
Reich K, Körber A, Maaßen D, Mrowietz U, Thaçi D, von Kiedrowski R
and Radtke MA: Definition of psoriasis severity in routine clinical
care: Current guidelines fail to capture the complexity of
long-term psoriasis management. Br J Dermatol. 179:1385–1391. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carrera CG, Dapavo P, Malagoli P, Naldi L,
Arancio L, Gaiani F, Egan CG, Di Mercurio M and Cattaneo A: PACE
study: Real-life Psoriasis Area and Severity Index (PASI) 100
response with biological agents in moderate-severe psoriasis. J
Dermatolog Treat. 29:481–486. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Billi AC and Gudjonsson JE: Adalimumab in
Psoriasis: How much is enough? J Invest Dermatol. 139:19–22. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Esposito M, Prignano F, Rongioletti F,
Hansel K, Bianchi L, Pescitelli L, Lazzeri L, Ricceri F, Mugheddu
C, Bavetta M, et al: Efficacy and safety of adalimumab after
failure of other anti-TNFα agents for plaque-type psoriasis:
Clinician behavior in real life clinical practice. J Dermatolog
Treat. 6:1–5. 2018. View Article : Google Scholar
|
|
5
|
Ruiz V, Velásquez M and Barrera LF:
Immunogenetic aspects of psoriasis with emphasis on micro-RNA.
Inmunol. 33:137–146. 2014.
|
|
6
|
Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A
and Gelfand JM: The risk of cancer in patients with psoriasis: A
population-based cohort study in the health improvement network.
JAMA Dermatol. 152:282–290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rønholt K and Iversen L: Old and new
biological therapies for psoriasis. Int J Mol Sci. 18(pii):
E22972017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farshid G, Prowse P and True B:
Epithelioid myxofibrosarcoma developing at the injection site of
Adalimumab therapy for psoriatic synovitis. Eur J Rheumatol.
5:131–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krishna SM and Kim CN: Merkel cell
carcinoma in a patient treated with adalimumab: Case report. Cutis.
87:81–84. 2011.PubMed/NCBI
|
|
10
|
Amadu V, Satta R, Montesu MA and Cottoni
F: Kaposi's sarcoma associated with treatment with adalimumab.
Dermatol Ther (Heidelb). 25:619–620. 2012. View Article : Google Scholar
|
|
11
|
Bret J, Hernandez J, Aquilina C,
Zabraniecki L and Fournie B: Kaposi's disease in a patient on
adalimumab for rheumatoid arthritis. Joint Bone Spine. 76:721–722.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bonovas S, Minozzi S, Lytras T,
González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L,
Cinquini M, Marino V, et al: Risk of malignancies using anti-TNF
agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing
spondylitis: A systematic review and meta-analysis. Expert Opin
Drug Saf. 15 (Suppl 1):35–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
